Restorgenex Corporation (RESX) 3.2600 $RESX
RestorGenex to Present at the AACR Conference on Targeting the PI3K-mTOR Network in Cancer
Business Wire - Mon Sep 15, 6:00AM CDT
RestorGenex Corporation (OTCQB:RESX), a specialty biopharmaceutical company initially focused on developing products for oncology, dermatology, ophthalmology and women's health, today announced that David Sherris, Ph.D., RestorGenex's chief scientific officer, will present scientific data on the Company's proprietary RES-529 program in oncology. Dr. Sherris' presentation at the American Association for Cancer Research Conference on Targeting the PI3K-mTOR Network in Cancer is scheduled for Monday, September 15, 2014 at 4:30 pm (EST) at the Sheraton Philadelphia Downtown Hotel, Philadelphia, Pennsylvania.
RestorGenex to Present at Rodman & Renshaw Global Investment Conference
Business Wire - Thu Sep 04, 6:00AM CDT
RestorGenex Corporation (OTCQB: RESX), a specialty biopharmaceutical company initially focused on developing products for dermatology, ophthalmology and women's health, today announced that Stephen M. Simes, RestorGenex's CEO, will present a corporate overview at the Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co.
RestorGenex Reports Second Quarter 2014 Financial Results
Business Wire - Thu Aug 14, 3:05PM CDT
RestorGenex Corporation (OTCQB: RESX), a specialty biopharmaceutical company initially focused on developing products for dermatology, ophthalmology and women's health, today reported on its cash balance as of June 30, 2014 and its financial results for the second quarter of 2014.
RestorGenex Appoints Mark Weinberg, MD, MBA Senior Vice President of Clinical Development
Business Wire - Mon Aug 04, 5:30AM CDT
RestorGenex Corporation (OTCQB: RESX), a specialty biopharmaceutical company initially focused on developing products for dermatology, ophthalmology and women's health, announced today the appointment of Mark Weinberg MD, MBA as Senior Vice President of Clinical Development.
RestorGenex Announces Closing of its Private Placement of Common Stock
Business Wire - Tue Jul 15, 6:00AM CDT
RestorGenex Corporation (OTCQB: RESX), a specialty biopharmaceutical company, announced today that it closed its private placement, which raised approximately $35.6 million in gross proceeds. RestorGenex received net proceeds of approximately $31.3 million, after deducting placement agent fees and other offering expenses. RestorGenex sold 8,895,685 shares of its common stock and warrants to purchase up to 2,668,706 additional shares of its common stock in a private placement to institutional and accredited investors. Each unit, consisting of one share of common stock and a warrant to purchase 0.3 of a share of common stock, was sold for a purchase price of $4.00. Each full warrant is exercisable immediately into one common share of common stock at an exercise price of $4.80 per share and will expire four years from its date of issuance. As a result of closing this financing, RestorGenex currently has outstanding approximately 18.4 million shares of common stock and 24.5 million fully diluted shares.
RestorGenex Announces Management Changes
Business Wire - Wed Jul 09, 6:00AM CDT
RestorGenex Corporation (OTCQB: RESX), a specialty biopharmaceutical company initially focused on developing products for dermatology, ophthalmology and women's health, announced today several management changes.
RestorGenex to Present at the AACR Conference on Targeting the PI3K-mTOR Network in Cancer
Business Wire - Mon Sep 15, 6:00AM CDT
RestorGenex Corporation (OTCQB:RESX), a specialty biopharmaceutical company initially focused on developing products for oncology, dermatology, ophthalmology and women's health, today announced that David Sherris, Ph.D., RestorGenex's chief scientific officer, will present scientific data on the Company's proprietary RES-529 program in oncology. Dr. Sherris' presentation at the American Association for Cancer Research Conference on Targeting the PI3K-mTOR Network in Cancer is scheduled for Monday, September 15, 2014 at 4:30 pm (EST) at the Sheraton Philadelphia Downtown Hotel, Philadelphia, Pennsylvania.
RestorGenex to Present at Rodman & Renshaw Global Investment Conference
Business Wire - Thu Sep 04, 6:00AM CDT
RestorGenex Corporation (OTCQB: RESX), a specialty biopharmaceutical company initially focused on developing products for dermatology, ophthalmology and women's health, today announced that Stephen M. Simes, RestorGenex's CEO, will present a corporate overview at the Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co.
RestorGenex Reports Second Quarter 2014 Financial Results
Business Wire - Thu Aug 14, 3:05PM CDT
RestorGenex Corporation (OTCQB: RESX), a specialty biopharmaceutical company initially focused on developing products for dermatology, ophthalmology and women's health, today reported on its cash balance as of June 30, 2014 and its financial results for the second quarter of 2014.
RestorGenex Appoints Mark Weinberg, MD, MBA Senior Vice President of Clinical Development
Business Wire - Mon Aug 04, 5:30AM CDT
RestorGenex Corporation (OTCQB: RESX), a specialty biopharmaceutical company initially focused on developing products for dermatology, ophthalmology and women's health, announced today the appointment of Mark Weinberg MD, MBA as Senior Vice President of Clinical Development.
RestorGenex Announces Closing of its Private Placement of Common Stock
Business Wire - Tue Jul 15, 6:00AM CDT
RestorGenex Corporation (OTCQB: RESX), a specialty biopharmaceutical company, announced today that it closed its private placement, which raised approximately $35.6 million in gross proceeds. RestorGenex received net proceeds of approximately $31.3 million, after deducting placement agent fees and other offering expenses. RestorGenex sold 8,895,685 shares of its common stock and warrants to purchase up to 2,668,706 additional shares of its common stock in a private placement to institutional and accredited investors. Each unit, consisting of one share of common stock and a warrant to purchase 0.3 of a share of common stock, was sold for a purchase price of $4.00. Each full warrant is exercisable immediately into one common share of common stock at an exercise price of $4.80 per share and will expire four years from its date of issuance. As a result of closing this financing, RestorGenex currently has outstanding approximately 18.4 million shares of common stock and 24.5 million fully diluted shares.
RestorGenex Announces Management Changes
Business Wire - Wed Jul 09, 6:00AM CDT
RestorGenex Corporation (OTCQB: RESX), a specialty biopharmaceutical company initially focused on developing products for dermatology, ophthalmology and women's health, announced today several management changes.
